GRAYZEL DAVID S. 4
4 · Aerovate Therapeutics, Inc. · Filed Jan 5, 2023
Insider Transaction Report
Form 4
GRAYZEL DAVID S.
Director
Transactions
- Award
Stock Option (Right to Buy)
2023-01-03$18.08/sh+2,654$47,984→ 2,654 totalExercise: $27.03Exp: 2033-01-02→ Common Stock (2,654 underlying)
Footnotes (2)
- [F1]This option was awarded in lieu of cash compensation pursuant to the Issuer's Non-Employee Director Compensation Policy. The shares underlying such option shall vest and become exercisable in four substantially equal installments, with the first installment vesting on March 31, 2023, the second installment vesting on June 30, 2023, the third installment vesting on September 30, 2023, and the fourth installment vesting on December 31, 2023.
- [F2]This option was granted to the Reporting Person, a director of the Issuer. The proceeds of any sale of shares of common stock issued to the Reporting Person upon exercise of this option will be transferred to Atlas Venture Life Science Advisors, LLC and as such, the Reporting Person disclaims ownership of such securities reported herein for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, except to the extent of his pecuniary interest therein, if any.